UniQure gets review date and adcomm; Inovia's stock surges after approval

Plus news about AbbVie, Gilead and Tiziana Life Sciences. FDA gives uniQure a review date and adcomm: The agency will decide whether or not to approve UniQure’s high-profile Huntington’s disease gene therapy by May 1 ...